Obesity mechanisms, Noubar takeaways, scleroderma platform trial: a BioCentury podcast

There’s a tectonic shift happening in obesity research and drug development, BioCentury Editor in Chief Simone Fishburn said on the latest BioCentury This Week podcast. Fishburn and colleagues Karen Tkach Tuzman and Selina Koch discuss how the success of obesity therapies from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) and Eli Lilly and Co. (NYSE:LLY) targeting the incretin axis has galvanized a wave of drug development with different molecular targets as well as last week’s threshold-setting cardiovascular outcomes trial data from Novo and recent obesity deals by the two companies.   

BioCentury’s editors also discuss takeaways from Fishburn’s conversation with Flagship Pioneering’s Noubar Afeyan on The BioCentury Show, plus the Scleroderma Research Foundation’s plans to bring the platform trial model to scleroderma. 

BioCentury This Week is sponsored by the BioCentury-BayHelix East-West BioPharma Summit, which takes place in Cambridge, Mass., Oct 2-4.  For information on how to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.